ATE94763T1 - Medikament zur behandlung von fibrotischer stoerung und antifibrotische verbindung. - Google Patents

Medikament zur behandlung von fibrotischer stoerung und antifibrotische verbindung.

Info

Publication number
ATE94763T1
ATE94763T1 AT89300476T AT89300476T ATE94763T1 AT E94763 T1 ATE94763 T1 AT E94763T1 AT 89300476 T AT89300476 T AT 89300476T AT 89300476 T AT89300476 T AT 89300476T AT E94763 T1 ATE94763 T1 AT E94763T1
Authority
AT
Austria
Prior art keywords
interferon
treatment
fibrotic disorder
drug
human
Prior art date
Application number
AT89300476T
Other languages
English (en)
Inventor
Brian Berman
Matthew R Duncan
Original Assignee
Baker Cummins Dermatolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Cummins Dermatolog filed Critical Baker Cummins Dermatolog
Application granted granted Critical
Publication of ATE94763T1 publication Critical patent/ATE94763T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
AT89300476T 1988-01-25 1989-01-19 Medikament zur behandlung von fibrotischer stoerung und antifibrotische verbindung. ATE94763T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14797388A 1988-01-25 1988-01-25
EP89300476A EP0328255B1 (de) 1988-01-25 1989-01-19 Medikament zur Behandlung von fibrotischer Störung und antifibrotische Verbindung

Publications (1)

Publication Number Publication Date
ATE94763T1 true ATE94763T1 (de) 1993-10-15

Family

ID=22523687

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89300476T ATE94763T1 (de) 1988-01-25 1989-01-19 Medikament zur behandlung von fibrotischer stoerung und antifibrotische verbindung.

Country Status (6)

Country Link
EP (1) EP0328255B1 (de)
JP (1) JPH021411A (de)
AT (1) ATE94763T1 (de)
AU (2) AU2855189A (de)
CA (1) CA1327746C (de)
DE (1) DE68909267T2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89662A (en) * 1989-03-19 1997-11-20 Interpharm Lab Ltd Kiryat Weiz Pharmaceutical compositions comprising interferon-beta
US5227158A (en) * 1991-06-10 1993-07-13 Genentech, Inc. Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon
AU669132B2 (en) * 1991-10-11 1996-05-30 Mark Cedric Gillies Treating ophthalmic fibrosis using interferon-alpha
US5863530A (en) * 1991-10-11 1999-01-26 Spruson & Ferguson Treating ophthalmic fibrosis using interferon-α
JPH07501320A (ja) * 1991-10-11 1995-02-09 ギリーズ，マーク・セドリック インタ−フェロン・アルファによる眼線維症の治療
GB2304342A (en) * 1995-08-18 1997-03-19 Univ Manchester Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
US20020025316A1 (en) 1995-08-18 2002-02-28 Ferguson Mark Williams James Pharmaceutical composition containing inhibitors of interferon-gamma
EP0795332B1 (de) * 1996-03-14 2005-06-01 Mondobiotech Interferon SA Medizinische Verwendung von Gamma-Interferon im interstitiellen Lungenerkrankungen
JP2003508489A (ja) * 1999-09-09 2003-03-04 ハダジツト・メデイカル・リサーチ・サービシズ・アンド・デベロツプメント・カンパニー・リミテツド 創傷治癒の増進
HRP20030426A2 (en) * 2000-12-06 2005-04-30 Applied Research Systems Ars Holding N.V. Use of sarp-1 for the treatment and/or preventionof scleroderma
KR20040019069A (ko) * 2001-07-20 2004-03-04 인터뮨, 인크. 간섬유증의 치료 방법
AU2003258305A1 (en) * 2002-08-28 2004-03-19 Intermune, Inc. Combination therapy for treatment of fibrotic disorders
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3436638C2 (de) * 1984-10-05 1992-10-08 Bioferon biochemische Substanzen GmbH & Co, 7958 Laupheim Verwendung von Interferon-gamma (IFN-gamma) enthaltenden Präparationen zur Behandlung rheumatischer Erkrankungen
JPH052648A (ja) * 1991-06-25 1993-01-08 Kobe Steel Ltd 画像データ処理装置
JP3062305B2 (ja) * 1991-06-26 2000-07-10 キヤノン株式会社 眼底カメラ
JPH054380A (ja) * 1991-06-28 1993-01-14 Fujitsu Ltd 書体選択方式

Also Published As

Publication number Publication date
JPH0561254B2 (de) 1993-09-06
DE68909267T2 (de) 1994-04-28
DE68909267D1 (de) 1993-10-28
EP0328255A1 (de) 1989-08-16
CA1327746C (en) 1994-03-15
AU6820190A (en) 1991-03-14
AU2855189A (en) 1989-07-27
AU630530B2 (en) 1992-10-29
JPH021411A (ja) 1990-01-05
EP0328255B1 (de) 1993-09-22

Similar Documents

Publication Publication Date Title
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
ATE222770T1 (de) Pharmazeutische zubereitung für die subkutane, intramuskuläre oder intradermale verabreichung von faktor viii
DE68909267D1 (de) Medikament zur Behandlung von fibrotischer Störung und antifibrotische Verbindung.
ZA878295B (en) Treatment of immuno-resistant disease
ATE183087T1 (de) Verwendung von beta-hydroxy-beta- methylbutyratsäuere zur förderung der stickstoffzurückhaltung beim menschen
EP0317568A4 (de) Verwendung von Granulozyt-Makrophagen-Kolonie Erregenden Faktor zur Herstellung eines Medikaments zur Behandlung von Bakterieller krankheiten.
ZA90600B (en) Treatment of leukocyte dysefunction with gm-csf
ATE126061T1 (de) Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.
MY106603A (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
DE60028559D1 (de) Behandlung von multiplersklerose mit einer kombination von interferon und wachstumshormone
KR870010871A (ko) 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법
KR900701311A (ko) 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법
KR900012628A (ko) 감마 인터페론의 유효량을 함유하는 복강내 투여용 난소암 치료제
Raptopoulou et al. Interferon treatment of chronic active hepatitis B: Effect of a 6 month therapeutic regimen
MY119359A (en) Use of consensus interferon for reducing the side effects of interferon treatment in viral hepatitis.
IT1236834B (it) Complessi del 4-idrossi-2-metil-n--2-piridinil-2-h,2-benzotiazina-3- carbossiammide-1,1-diossido con cilodestrine, aventi azione anti- infiammatoria, procedimento per la loro preparazione e relative composizioni farmaceutiche.
Fujita et al. A clinical experience of fosfomycin tablet on cystitis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties